Last reviewed: June 30, 2026 Last updated: June 30, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
it's a medical therapy that requires expert oversight
For instance, patients with liver disease may experience fatigue, jaundice, or abdominal swellingsymptoms related to hepatic dysfunction rather than the elevated B12 itself
Other flags are autoimmune diseases, infections, recent surgery, blood thinners, and kidney or liver impairment
Regulatory Considerations Current Regulatory Status and Legal Framework The regulatory status of BPC-157 and TB-500 varies significantly across different jurisdictions and continues to evolve as regulatory agencies assess these compounds
This approach is entirely off-label and unvalidated, but it reflects the creative problem-solving that patients pursue when conventional options fail
